

# African AIDS Vaccine Program (AAVP)


*Round table Luncheon*

*Hosted by Her Excellency Mrs Jeannette Kagame,*

*First Lady of Rwanda &*

*High Representative for AAVP*

*11 June 2008*



**Established 2000**

[http://www.who.int/vaccine\\_research/diseases/hiv/aavp/en/](http://www.who.int/vaccine_research/diseases/hiv/aavp/en/)



**World Health  
Organization**



**UNAIDS**  
JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS


UNHCR  
UNICEF  
WFP  
UNDP  
UNFPA  
UNODC  
ILO  
UNESCO  
WHO  
WORLD BANK

# The AAVP Vision and Mission

**Vision**: An AIDS–Free Africa through an Effective Vaccine“

**Mission**: *The AAVP is a network of African HIV vaccine stakeholders, committed to HIV vaccine development for Africa, through research, advocacy, partnership, and contribution to capacity strengthening and policy development.*

# The AAVP Structure (5 year strategic plan 2006–2011)



\* To be moved from WHO/Geneva to an African location in 2009




# Uniqueness of the AAVP

- Developing advocacy strategies & communication tools on HIV vaccines specifically tailored for African communities
- Networking people and institutions on HIV prevention
- Promoting the development of appropriate candidate vaccines for Africa
- Facilitating the preparation for clinical trials through capacity building
- Developing strategies for future access to HIV vaccines in Africa

# National AIDS Vaccine Plans

● January	2001	Nigeria
● July	2001	Tanzania
● October	2001	Zambia
● September	2002	Cote D'Ivoire
● October	2002	Ethiopia
● November	2002	Cameroon
● September	2003	Uganda (update)
● March	2006	Uganda (update)
● July	2004	Kenya
● September	2004	Tanzania (update)
● December	2004	Botswana
● March	2005	Kenya





# AAVP Policy documents, Publications & Support for Young African Scientists


- Guidance document on **National Vaccine** Plan Template
- Policy document on role of **HIV subtypes** in vaccines
- Obstacles to enrollment of **women and adolescents** in vaccine clinical trials
- Trainings & inventory (biomedical, GCP, regulatory, ethics, scientific)
- Site development including support of other trials e.g. malaria or TB which could have benefit to HIV vaccine trials
- Support targeted research via institutional and regional collaboration (new AAVP collaborating centers):  
[http://www.who.int/vaccine\\_research/diseases/hiv/aavp/aavp\\_full\\_applications/en/index.html](http://www.who.int/vaccine_research/diseases/hiv/aavp/aavp_full_applications/en/index.html)

# Plans for 2008–2009

- Supporting the implementation of National AIDS Vaccine Plans
- Strengthening advocacy and addressing community issues
- Supporting capacity building (GCP, regulatory, ethics)
- Strengthening vaccine clinical trial sites development, building on synergies between HIV, TB and malaria vaccine R&D
- Promoting and supporting targeted research via institutional and regional collaboration (AAVP Collaborating Centers)

# Sources of the AAVP Funding


## CONTRIBUTIONS TO AAVP (2003-2007) USD 7,622,000





# Progress in number of African countries participating in vaccine trials

2000 (AAVP initiated)

2008



-  Countries currently involved in vaccine trials
-  Countries preparing for vaccine trials

# Estimated Financial Resources Required 2007–2009

Work Areas/AAVP Collaborating Centers	Estimated Financial Resources Required (in US\$ millions)		
	2008	2009	Total
Country-based strategic planning	.50	.70	1.20
Regulatory issues	.50	.70	1.20
Biomedical research	.50	.75	1.25
Communication and media	.40	.45	.85
Ethics, law and human rights	.40	.45	.85
Global coordination and Programme management	.70	.70	1.40
<b>Total</b>	<b>3.0</b>	<b>3.75</b>	<b>6.75</b>

**Initiative for Vaccine Research (IVR)**

[WHO](#) > [Programmes and projects](#) > [Initiative for Vaccine Research \(IVR\)](#) > [Selection of Diseases in IVR Portfolio](#) > [WHO-UNAIDS HIV Vaccine Initiative](#)

**The African AIDS Vaccine Programme (AAVP)**

Highlights



**Appointment and visit of the high representative for AAVP**

In 2007 the AAVP Strategic Plan identified the need for a high level AAVP advocate "AAVP High Representative" to advocate for the AAVP and help in raising funds in and outside of Africa. In October Her Excellency Jeannette Kagamé, the first Lady of Rwanda, agreed to act as the AAVP High Representative and advocate for the programme in order to raise funds within and outside Africa.

On the 13th of March 2008, Her Excellency paid a visit to WHO's Geneva headquarters. She met with the heads of both WHO and UNAIDS. As High Representative, she will help the Programme reach a wider audience to inform, educate and advocate in favour of an AIDS vaccine for Africa. Her efforts will also help garner additional political and financial support. As the continent most affected by HIV/AIDS, it is critical that Africa is part of the process of HIV vaccine research and development so that a future vaccine is effective there.

- [Related press release \[pdf 85kb\]](#)

# Acknowledgement

## Steering Committee Members:

Pontiano Kaleebu, Uganda/**Chair**

Alash'le Abimiku, Nigeria/USA/**Co-Chair**

John Nkengasong, Cameron/USA

Carolyn Williamson, S. Africa

Shenaaz El Halabi, Botswana

Sinata Koulla-Shiro, Cameroon

Coumba Toure Kane, Senegal

Saidi Kapiga, Tanzania/UK

## WHO/UNAIDS Secretariat

Marie-Paule Kieny

Cate Hankins

Saladin Osmanov

Coumba Touré

Heather Monnet

- **AIDS Vaccine Family**  
*(The Global Enterprise)*
- **AAVP Sponsors**